Cat. No. 6058
Biological Activityα5β1 integrin receptor antagonist. Reduces liver metastasis and improves survival in combination with 5-FU (Cat. No. 3257) in a mouse model of colon cancer. Reduces MLL tumor growth in rats and decreases tumor volume of human MDA-MB-231 cell xenografts in mice.
(Modifications: Pro-1 = N-terminal Ac, Asn-5 = C-terminal amide)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
Khalili et al (2006) A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol.Cancer Ther. 5 2271. PMID: 16985061 .
Stoeltzing et al (2003) Inhibition of integrin α5β1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int.J.Cancer. 104 496. PMID: 12584749.
Livant et al (2000) Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res. 60 309. PMID: 10667582.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses ATN 161 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: ATN 161, supplier, ATN161, α5β1, integrin, receptors, alpha5beta1, a5b1, antagonists, antagonism, Tocris Bioscience, Integrin Inhibitor products
Find multiple products by catalog number
New Products in this Area
Dual α9β/1α4β1 integrin inhibitor; preferentially mobilizes HSCsFSL 1
TLR2/6 agonist (also a putative TLR10 ligand)
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.